Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of PHP-303 in Healthy Subjects
NCT03627845Phase 1Completed
- Sponsor
- pH Pharma Co., Ltd.
- Start
- Aug 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in alpha-1 antitrypsin deficiency (AATD) comparing PHP-303 with Placebo (2 arms). Primary endpoints: Incidence of Adverse Events up to 9 weeks, Number of patients with abnormal ECG up to 9 weeks and 7 more. Started Aug 2018; status: completed.
02
Drugs
PHP-303
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT03627845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03627845.